The Pharmacy Times® Atopic Dermatitis Resource Center is a comprehensive resource for clinical news and expert insights on treatments for atopic dermatitis.
March 22nd 2023
The primary outcome of the study includes an IGA score of 0 or 1, which indicated clear or almost clear skin, respectively, with a reduction, from baseline to week 16.
Lebrikuzumab Found to Maintain Durable Skin Clearance When Dosed Every 4 Weeks in Atopic Dermatitis
September 14th 2022ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.
Read More